Calcium/calmodulin-dependent protein kinase II downregulates both calcineurin and protein kinase C-mediated pathways for cytokine gene transcription in human T cells by unknown
Brief DeBnitive  Report 
Calcium/Calmodulin-dependent Protein Kinase II Downregulates 
Both Calcineurin and Protein Kinase C-mediated 
Pathways for Cytokine Gene Transcription in Human T  Cells 
By Nobuaki  Hama,  Fotini  Paliogianni,  Barri J.  Fessler, 
and Dimitrios  T.  Boumpas 
From the Kidney Disease Section, Metabolic Diseases  Branch, National  Institute of  Diabetes and Digestive 
and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892 
Summary 
Engagement of the T cell receptor for antigen activates phospholipase C resulting in an increase 
in intracellular flee calcium concentration ([Ca  2+ ]i) and activation of protein kinase C  (PKC). 
Increased  [Ca2+]i  activates  Ca2+/calmodulin-dependent kinases  including the multifunctional 
Ca2+/calmodulin-dependent protein kinase II (CaM-K II), as well as calcineurin,  a type 2B pro- 
tein phosphatase. Recent studies have identified calcineurin as a key enzyme for interleukin (IL)-2 
and II:4 promoter activation. However, the role of CaM-K II remains unknown. We have used 
mutants of these kinases and phosphatases ('yB*CaM-K and ACaM-AI, respectively) to explore 
their relative role in cytokine gene transcription and their interactions with PKC-dependent sig- 
naling systems. 7B*CaM-K and ACaM-AI, known to exhibit constitutive Ca2+-independent ac- 
tivity, were cotransfected (alone or in combination) in Jurkat T cells with a plasmid containing 
the intact Ib2 promoter driving the expression of the chloramphenicol acetyltransferase reporter 
gene. Cotransfection of 3,B*CaM-K with the IL-2 promoter construct downregulated its tran- 
scription in response to stimulation with ionomycin and phorbol myristate acetate (PMA). The 
inhibitory effect of CaM-K II on I1:2 promoter was associated with decreased transcription of 
its AP-1 and NF-AT transactivating pathways. Under the same conditions, ACaM-AI superin- 
duced I1:2 promoter activity (approximately twofold increase). When both mutants were used 
in combination, "yB*CaM-K inhibited the induction of the I1:2 promoter by ACaM-AI.  Similar 
results were obtained when a construct containing the I1:4 promoter also was used. yB*CaM-K 
also downregulated the activation of AP-1 in response to transfection with a constitutively active 
mutant of PKC or stimulation with PMA. These results suggest that CaM-K II may exert nega- 
tive influences on cytokine gene transcription in human T cells, and provide preliminary evidence 
for negative cross-talk  with the calcineurin-  and PKC-dependent signaling systems. 
I 
1:2  gene  transcription is  controlled by  a promoter re- 
gion extending •326  bp upstream of the transcription start 
site. This promoter region contains binding sites for at least 
five nuclear proteins including nuclear factors NF-AT, Oct-l, 
NF-~B, AP-1, and CD28KC (1, 2). Both an increase of cyto- 
plasmic calcium (Ca  2+) and activation of protein kinase C 
(PKC)  are required for its activation in resting T  cells. 
Recent studies have established that the Ca2+/calmodulin - 
dependent protein kinase II (CaM kinase II) is the general 
or multifunctional kinase of CaZ+-signaling systems (reviewed 
in 3). CaM kinase II is present in most tissues as an oligomer 
composed of 6-12 subunits, depending on the isoform and 
tissue. All 11 isoforms described to date (c~, o~33, fl, B', 3'A, 
yB, 3'c, 8A, /iB or ~i3, /ic or/i2, 6D or 64) share a highly con- 
served catalytic domain at the NH2-terminal portion of the 
molecule, an  autoinhibitory sequence  overlapping with a 
calmodulin binding region and an association domain which 
is important for the formation of the holoenzyme (3-5). After 
an increase in intracellular flee Ca  2+ concentration ([Ca2+]i), 
Ca  2§  activates CaM kinase II causing the kinase 
to phosphorylate itself on the Thr  286 (~ isoform) or Thr  2s7 
(B and "y isoforms) site of the autoinhibitory domain. This 
phosphorylation event results in disruption of the autoinhibi- 
tory domain and Ca2+-independent  activity (m20-80%  of 
maximal CaZ+-stimulated activity)  (3). Mutations at Thr  TM 
(e.g., change to Asp) result in mutants with 20-40% activity 
in the absence of Ca  2+/calmodulin stimulation (3). Constit- 
utively active mutants of CaM kinase II can be used to inves- 
tigate its role in the transcriptional regulation and to isolate 
the  potential  effects  of  this  enzyme  from  other  Ca  2+- 
dependent  events (6). 
Increase in [Ca2+]i and activation of calmodulin may also 
activate  Ca2+/calmodulin-dependent phosphatases  such  as 
calcineurin, a type 2B serine/threonine protein phosphatase. 
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a key enzyme needed for Ib2 and II:4 promoter activity (7-9). 
In addition to its effects on the intact II:2 promoter, calcineurin 
can separately lead to the transactivation of nuclear factors 
NF-AT and Oct-1 (NF-IL2A, OAP/Oct-1). More recent data 
have also suggested that calcineurin may act in synergy with 
PMA to inactivate Ir,.B/MAD3, an inhibitor of NF-gB, thereby 
resulting in net activation of the NF-gB (10). 
Whereas the role of CaM kinase II has been well defined 
in neuronal tissues, its role in T cell activation remains largely 
unknown. In human lymphocytes, stimulation via the TCK 
or with calcium ionophores increases CaM kinase II activity 
(5,  11). Using constitutively active mutants of CaM kinase 
II, calcineurin, and PKC, we asked whether CaM kinase II 
is involved in the regulation of Ib2 and Ib4 promoter tran- 
scription and its influence on the effects of calcineurin- and 
PKC-dependent signaling systems. Our data indicate that CaM 
kinase downregulates the transcription of these cytokines and 
provides  preliminary evidence  for cross-talk  among  these 
pathways. 
Materials  and Methods 
Cell Culture.  Human Jurkat T cells were cultured in RPMI- 
1640 supplemented with 10%  heat-inactivated FCS, 25 /~g/ml 
gentamicin, and 5  x  10 -s M 2-ME (Sigma Chemical Co., St. 
Louis, MO). 
Plasmid Constructs.  The reporter plasmid  II.-2 CAT contains the 
human IL-2  promoter (base pairs -448 to +43) directing the tran- 
scription of the chloramphenicol  acetyltransferase  (CAT) gene. This 
plasmid also includes an SV40 polyadenylation  site between vector 
sequences and -448 of the IL-2  promoter to prevent vector-depen- 
dent transcription from contributing to the observed CAT activity 
(7). Plasmid AP-1 CAT (TRE-tk CAT) (a gift from Dr. M. Karin, 
University of California at San Diego, La Jolla, CA) contains a 
synthetic oligonucleotide from  -73  to  -65 of the human col- 
lagenase gene cloned into the HindlII/BamHI cut of pBLCAT 2, 
which contains the Herpes simplex virus thymidine kinase pro- 
moter from position -109 to  + 51 in front of the CAT structural 
gene (12). Plasmid NF-AT CAT (a gift from Dr. G. R. Crabtree, 
Stanford University, Stanford, CA)  has  three  copies of NF- 
AT-binding site containing 5' 11.,2 sequences -255 to -285 linked 
to the IL-2 promoter sequences from  -72 to  +47 linked to the 
CAT gene (8). Plasmid ID4 CAT (a gift from Dr. G. Thyphronitis, 
Institute Pasteur, Lille, France) contains the human IL-4 promoter 
(base pairs -418 to  +50) cloned into the Not I site of pUMSPL, 
which is on a pSVOCAT-based vector that contains the upstream 
sequences of the c-mos gene to stop read-through transcription, 
and the polylinker of the pBluescript. Plasmid ~,B*CaM-K  (a gift 
from Dr. H. Schulman, Stanford University, Stanford, CA) is a 
constitutive mutant of the human T lymphocyte 'yBCaM kinase 
(5). EcoRl linkers  were added  to the ClaI-NotI fragment containing 
the full-length 3rBCaM kinase. This fragment was then inserted 
into pSRc~BKS, forming a complete 3~CaM kinase-SRcr expres- 
sion construct. Subsequently, Thr  2s7 was replaced with Asp using 
site-directed mutagenesis to make mutant 3,B*CaM-K. This mu- 
tation mimics the effect of autophosphorylation on disrupting the 
autoinhibitory domain and generates a CaM kinase which is sub- 
stantially Ca2+-independent. 3,~*CaM-K  was nearly 40% active in 
the  absence of Ca~+/calmodulin (5). In  cells stimulated with 
ionomycin and PMA, and transfected with 10/~g of-yB*CaM-K, 
the activity (determined  in cytoplasmic  extracts using the synthetic 
peptide substrate syntide that is recognized  by this kinase) was two- 
to threefold higher than in cells transfected with its vector (data 
not  shown). Plasmid double  mutant  (inactive/constitutive) 
3,sCaM-K (also a gift from Dr. H. Schulman) is the catalytically 
inactive mutant of 3,B*CaM-K. Double mutant 3,B*CaM-K was 
constructed by replacing  Lys  43 (which is a conserved residue essen- 
tial for catalytic activity) with Met in the ATP binding (catalytic) 
domain. Plasmid  ACaM-AI (a gift from Dr. R. L. Kincaid, Human 
Genome Sciences, Inc., Rockville, MD) is a deletion mutant of 
the catalytic subunit of the wild-type murine calcineurin, the se- 
quence of which has 99% homology to the corresponding human 
subunit. ACaM-AI lacks functional CaM-binding and autoinhibi- 
tory domains. This truncation was designed to mimic proteolyzed 
forms of the phosphatase known to have Ca  2+-independent, con- 
stitutive phosphatase activity in vitro (7). Plasmid APKCB  (a gift 
from Dr. M.-A. Muramatsu, University of Tokyo, Tokyo,  Japan) 
is the constitutively  active  mutant of PKCB which lacks the regula- 
tory domain (phorbol ester binding domain). APKC/J lacks the 
coding region for amino acids at positions 6-159 of PKCB (13). 
In control experiments, the expression vector alone was used. 
DNA Transfections.  Transfections  ofJurkat T cells were carried 
out by the DEAE-dextran method as previously  described (14). To 
monitor and control for transfection efficiency,  cells were cotrans- 
fected with pCMV.Gal which contains the CMV-IE promoter dir- 
ecting transcription of the bacterial  B-galactosidase  (~-gal) gene (7). 
CATAssay.  The CAT assay  was carried out as described  previ- 
ously (14). The CAT activity was then normalized to the ~8-gal 
activity. 
Results 
"y~*CaM.K Does Not Substitute for The Ca2+-deFendent  Sig- 
naling Pathway  for IL2 Promoter Transactivation.  In the Jurkat 
model system, ACaM-AI can substitute for the Ca  2+ signal 
required for 1I.-2 gene transcription (7, 8, 14). To investigate 
the role of CaM kinase II in the activation of the II.-2 pro- 
moter, we cotransfected a plasmid containing the II,-2 pro- 
moter linked to the CAT gene along with plasmids ACaM- 
AI or "ys*CaM-K into  these cells.  Cells  were stimulated 
with ionomycin and/or PMA.  As  shown in  Fig.  1,  both 
ionomycin and PMA were required for IL-2 promoter activa- 
tion. ACaM-AI was able to partially substitute for the Ca  2+ 
ionophore (~50% activity as compared to stimulation with 
ionomycin and PMA). Furthermore, addition of ionomycin 
further induced IL-2 promoter activity by approximately two- 
fold (range 1.8-2.4)  suggesting that in addition to calcineurin 
other Ca2+-dependent pathways are also involved in IL-2 pro- 
moter activity. The effect of calcineurin was specific since 
it  did  not  affect  the  activity of the  unrelated  promoter 
pCMV.Gal (98.9  +  15.3% of activity of cells treated with 
the vector alone). As shown in the same figure, these pathways 
most likely do not involve CaM kinase,  since in similar ex- 
periments  3,s*CaM-K  not  only could  not  substitute  for 
ionomycin but, to the contrary, exerted a negative effect on 
the transactivation of IIr  promoter in response  to stimula- 
tion with ionomycin and PMA (Fig.  1) (see below). 
ys*CaM-K  Inhibits IL-2  Promoter Activation  by  Down- 
regulating Its Transactivating Pathways AP-1 and NF-AT  The 
transcription factors that bind to the AP-1 and NF-AT sites 
are critical for Ib2 gene expression (1). To determine whether 
the inhibitory effect of 3,B*CaM-K on 1I.-2 promoter was 
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esters to mediate the transactivation of the I1,2 promoter. Jurkat cells were 
transiently  transfected with 5/zg of plasmid  I1,2 CAT (which contains 
the I1,2 promoter driving the expression of CAT gene) alone or in combi- 
nation with plasmids ACaM-AI or ~/B*CaM-K (10 #g). Cells were stimu- 
lated with PMA alone or in combination with ionomycin. 
mediated by these c/s-acting elements, cells were transfected 
with constructs containing the intact 11,2 promoter or its 
AP-1  and  NF-AT  sites linked to  the  CAT reporter  gene. 
"yB*CaM-K decreased  the  activity of all  three constructs 
(Fig. 2). In four different experiments "),B*CaM-K decreased 
the activity of the I1,2 promoter construct by ,v50% (53.4 +_ 
9.2),  of the AP-1 by ,v70%  (68.5  +_  3.9),  and NF-AT by 
~35%  (34.2  +_  7.4).  The  downregulatory  effect  of 
~/B*CaM-K was specific since it did not affect the activity 
of the unrelated promoter pCMV.Gal (95.8  _+  9.3% of the 
activity of cells transfected with the vector alone). Further- 
more, cotransfection of the double mutant (inactive/consti- 
tutive) 3,BCaM-K did not downregulate the I1,2 promoter 
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Figure  2.  "/B*CaM-K  inhibits  IL-2 promoter  activation  by  down- 
regulating its transactivating pathways AP-1 and NF-AT. Cells were cotrans- 
fected with plasmids I1,2 CAT, AP-1 CAT or NF-AT CAT (5 #g) and 
qCB*CaM-K (10  /~g) or its vector,  and  stimulated  with ionomycin  and 
PMA.  Results  (expressed as percentage  of activity observed when cells 
were stimulated  in the presence of vector) were normalized  to the activ- 
ity of pCMV.Gal  which was used  to control for transfection  efficiency 
(mean  •  SE). 
activity (122.2  _  8.9%  of the activity of cells transfected 
with the vector alone in four independent experiments) (not 
shown). 
"ys*CaM-K  Downregulates the Transcription of Other Ca  2+- 
dependent Promoters.  In addition to II,2 promoter the Ca  2+ 
pathway is also involved in the regulation of other cytokine 
promoters such as I1,4, a Th2 promoter. Even though the 
signal transduction pathway may be different  in Ib2- and 
Ib4-producing Thl and Th2 clones, both pathways share 
the [Ca2+]i elevation (15). Recent data have suggested that 
calcineurin alone may upregulate the transcriptional activity of 
I1,4 (reference 9 and Paliogianni, F., N. Hama, G. J. Mavro- 
thalassitis, G. Thyphronitis, and D. T. Boumpas, manuscript 
in preparation). To determine the effects of 3'B*CaM-K on 
this promoter, Jurkat cells were transfected with a construct 
of II.-4 promoter linked to the CAT reporter gene. Similar 
to  Ib2,  transfection with 3,B*CaM-K resulted in  a small 
(•40%)  but reproducible inhibition of the transcriptional 
activity of the I1,4 promoter in response to ionomycin or 
ACaM-AI (Fig. 3). These data suggest that 3'B*  CaM-K may 
counteract the  effects  of calcineurin (and  probably  other 
Ca2+-pathways). 
")'B*CaM-K Counteracts the Effects of ACaM-AI on 11-,2 Pro- 
motet.  To further explore the interaction between calcineurin 
and CaM kinase, we cotransfected  Jurkat cells with the IL-2 
promoter  and  ACaM-AI  alone  or  in  combinatidn with 
3,B*CaM-K. In cells stimulated with ionomycin and PMA 
cotransfection with 3,B*CaM-K completely abolished the su- 
perinduction of I1.-2 promoter in the presence of ACaM-AI 
(Fig.  4).  Similar  to  its  effects  on  the  II_,2 promoter, 
yB*CaM-K  partially  downregulated the increase in the ac- 
tivity of the NF-AT construct in response to stimulation with 
ionomycin and PMA alone or in combination with ACaM-AI 
(not  shown).  These results provide further evidence  that 
~/B*CaM-K may counteract the effects of calcineurin depen- 
dent-pathways on T  cell activation. 
"yB*CaM-K Downregulates the Effects of PKC on  Transacti- 
ration of AP-1.  In contrast to NF-AT whereby Ca  2+ is es- 
sential for its activation, stimulation with phorbol esters alone 
is sufficient and more potent than ionomycin to induce AP-1 
activity (16, 17). To explore the interaction of CaM kinase 
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Figure 3.  ?B*CaM-K decreases 
the activity  of IL-4 promoter in 
response to activation with iono- 
mycin  or  ACaM-AI.  Cells  co- 
transfected  with  15  /xg of Ib4 
CAT (which  contains  11,4 pro- 
moter linked to the CAT gene) in 
combination  with  "yB*CaM-K 
and/or ACaM-AI (7.5/xg). 
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Figure 4.  "ys*CaM-K  coun- 
teracts the effects of ACaM-AI on 
II:2 promoter. Cells were cotrans- 
fected with II~2 CAT (5/~g) in 
combination  with  ACaM-AI 
and/or 'yB*CaM-K (10 #g) and 
stimulated  with ionomycin and 
PMA. Results (expressed as per- 
centage activity observed in cells 
transfected  with  vector  alone) 
were normalized to the activity of 
pCMV.Gal  which  was  used  to 
monitor for transfection ef~ciency 
(mean  •  SE). 
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Figure 6.  Both  3,s*CaM-K 
and ACaM-AI downregulate the 
transactivadon  of  AP-1 in response 
to stimulation with PMA. Cells 
were cotransfected with plasmids 
AP-1 CAT  (5  /~g), 3~B*CaM-K 
(10/tg)  and ACaM-AI (10 /~g) 
(alone or in combination),  and 
stimulated  with  PMA.  Results 
(expressed as a percentage activity 
observed in cells transfected with 
the  pSP,  ct  vector  alone)  were 
normalized  to  the  activity  of 
pCMV.Gal (mean  •  SE). 
II with PKC-dependent  pathways during the activation of 
T cells, Jurkat cells were cotransfected with an AP-1 con- 
struct linked to the CAT reporter gene alone or in combina- 
tion with constitutive active mutants of CaM kinase II, cal- 
cineurin,  and PKC (3'B'CaM-K,  ACaM-AI,  and APKC3, 
respectively).  As shown in Fig. 5, cotransfection with APKC3 
increased the baseline activity of AP-1 by approximately six- 
fold. Stimulation with PMA further induced the activity of 
AP-1. Under both conditions cotransftxn'ion  with 7B*CaM-K 
downregulated the AP-1 activity by ,,060%. In addition to 
3'B'CaM-K, ACaM-AI also downregulated the AP-1 activity 
in response to stimulation with PMA (,,o50% inhibition, Fig. 
6). As shown in the same figure, the downregulatory effects 
of ACaM-AI and 3,B*CaM-K were not synergistic. These 
data suggest that under certain conditions both calcineurin 
and CaM kinase II may downregulate PKC-dependent trans- 
activation pathways. 
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Figure 5.  3,B*CaM-K  downregulates the transactivation of AP-1 in re- 
sponse to cotransfection with APKQ8 and/or stimulation with PMA. Cells 
were cotransfected with plasmids AP-1 CAT (5/zg) in combination  with 
3,s*CaM-K (10/~g) and/or APKC3 (20/~g).  Data are representative of 
results in five independent  experiments. 
Discussion 
In this study we have presented evidence that CaM kinase 
II  may downregulate Ca  2+-  and  PKC-dependent transac- 
tivating pathways for cytokine gene transcription  in human 
T cells. The effect of CaM kinase II seems  to be spedfic since 
CaM kinase II does not affect the activity of the unrelated 
promoter pCMV.Gal. Furthermore, the double mutant (in- 
active/constitutive)  3,BCaM-K does not affect the IL-2 pro- 
moter activity, suggesting that inhibition  of gene transcrip- 
tion requires the presence of a catalytically active domain of 
CaM kinase II and it is not due to the competing effects of 
the vectors used in these experiments. These results provide 
a molecular basis for the previously reported negative effects 
of the Ca2+-pathway on T  cells, such as negative selection 
and anergy (18-20). 
IL-2 is one of the major growth factors for the cells of the 
immune system. Inadequate production of 1L-2 has significant 
consequences for the T  cells and may result in anergy and 
tolerance. Exogenous  IL-2 or costimulation via the CD28 
pathway may reverse these states suggesting  that the total 
amount of IL-2 produced in an immune response plays a crit- 
ical role in determining the extent of the anergy (20, 21). 
In addition to playing a major role in the physiological im- 
mune responses against foreign antigens IL-2 may also be in- 
volved in autoimmune phenomena. A stringent control of 
the production of Ib2 is therefore required to avoid excess 
production which may lead to breaking of tolerance and au- 
toimmune phenomena. 
Work from several laboratories has associated the lack of 
IL-2 production in anergic states to defects in the transactiva- 
tion of nuclear factors, AP-1 (22), NF-AT, and NF-KB (23). 
These results suggest that activation of CaM kinase II may 
provide an additional regulatory mechanism for the fine tuning 
of IL-2 production during T cell activation. It is possible that 
the downregulation of these transactivating pathways may 
be due, at least in part, to activation of CaM kinase II. Al- 
though in these experiments CaM kinase II only partially 
inhibited IL-2 transcription,  this may be su~cient to result 
in autocrine rather than paracrine levels of Ib2 production 
(20). Furthermore, the degree of inhibition may differ among 
different types or clones of T  cells. 
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T  cells through the CD28 pathway augments Ib2 produc- 
tion from autocrine to paracrine levels and prevents induc- 
tion of anergy (21). Although increases in [Ca~']i during ac- 
tivation through TCR will activate both caldneurin (which 
augments IL2 production) and CaM kinase II (which decreases 
it),  it is conceivable that  additional accessory stimuli (e.g., 
stimulation via CD2, CD5, or CD28) may shift the balance 
towards one or the other of these enzymes. 
Downregulation  of IL-4 production of CaM kinase II is 
also of interest. II,-4 is the other major T cell growth factor 
and is essential for the regulation of humoral immune re- 
sponses. Anergic T cells lose their responsiveness to II,-4 (20). 
Decreased production of II.-4 by CaM kinase II may be an 
additional proximal mechanism  to prevent proliferative re- 
sponse by these cells. 
This study has presented preliminary data on cross-talk be- 
tween the CaM kinase II and calcineurin signaling systems. 
During T cell activation the partial inhibition of IL-2 or II,-4 
promoter activity by CaM kinase II suggests that their effects 
may be exerted at more distal sites in the calcineurin regu- 
lated pathways. Calcineurin is known to activate several dis- 
crete transactivating pathways including NF-AT, Oct-1/OAP, 
and NF-KB and to downregulate the activity of AP-1 (7-10). 
Hashimoto et al.  (24) have shown that calcineurin is phos- 
phorylated by the autophosphorylated form of CaM kinase 
II. Whether these in vitro data have any relevance to explaining 
the attenuating  effects of CaM kinase II on calcinenrin  in 
vivo can not be addressed by these studies. 
Whereas it is well established that PKC may exhibit both 
negative and positive cross-talk with CaM kinase II (25), the 
effects of CaM kinase on PKC are less well characterized. 
Our data provide for the first time evidence that CaM kinase 
II may downregulate PKC-dependent pathways for T cell ac- 
tivation. Once more the partial inactivation of the PKC medi- 
ated AP-1 induction suggests that CaM kinase II more likely 
affects distal sites  in the PKC mediated pathway. 
In summary, our data have identified CaM kinase II as a 
potential candidate for some of the negative effects of the 
CF+-pathway on T cell activation. Furthermore,  these data 
provide indirect evidence for cross-talk between the calcium 
and the PKC pathways during T  call activation. Additional 
studies should further ddineate this interaction  and deter- 
mine its importance  for the activation  of T  cells. 
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